Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

ClinicalTrials.gov ID: NCT06699849

Public ClinicalTrials.gov record NCT06699849. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Apr 22, 2026, 9:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

Study identification

NCT ID: NCT06699849
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: CSL Behring; Industry
Enrollment: 70 participants

Conditions and interventions

Conditions

Sickle Cell Disease Vaso-occlusive Crisis

Interventions

CSL889 Biological
Placebo Drug

Biological · Drug

Eligibility (public fields only)

Age range: 12 Years and older
Sex: All
Healthy volunteers: Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 9, 2025
Primary completion: Oct 21, 2027
Completion: Oct 21, 2027
Last update posted: Apr 15, 2026

2025 – 2027

United States locations

U.S. sites: 14
U.S. states: 8
U.S. cities: 11

Facility	City	State	ZIP	Site status
University of California Irvine	Orange	California	92868	Not yet recruiting
Golisano Children's Hospital	Fort Myers	Florida	33908	Recruiting
The Foundation for Sickle Cell Disease	Hollywood	Florida	33023-6703	Recruiting
University of Maryland	Baltimore	Maryland	21201	Recruiting
Detroit Medical Center	Detroit	Michigan	48201	Recruiting
Henry Ford Health System	Detroit	Michigan	48202	Recruiting
Mount Sinai Medical Center	New York	New York	10029	Recruiting
Jacobi Medical Center	The Bronx	New York	10461	Recruiting
Albert Einstein College of Medicine	The Bronx	New York	10467	Withdrawn
University of Cincinnati	Cincinnati	Ohio	45267	Recruiting
The Ohio State University	Columbus	Ohio	43085	Recruiting
University of Pittsburgh	Pittsburgh	Pennsylvania	15224	Recruiting
Hillman Cancer Center	Pittsburgh	Pennsylvania	15232	Recruiting
Virginia Commonwealth University	Richmond	Virginia	23298	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06699849, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 15, 2026 · Synced Apr 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06699849 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →